Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,147
Employees1,147
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,147
Employees1,147

EXEL Key Statistics

Market cap
11.04B
Market cap11.04B
Price-Earnings ratio
17.21
Price-Earnings ratio17.21
Dividend yield
Dividend yield
Average volume
2.69M
Average volume2.69M
High today
$42.00
High today$42.00
Low today
$40.66
Low today$40.66
Open price
$41.66
Open price$41.66
Volume
2.57M
Volume2.57M
52 Week high
$49.62
52 Week high$49.62
52 Week low
$31.90
52 Week low$31.90

Stock Snapshot

With a market cap of 11.04B, Exelixis(EXEL) trades at $40.88. The stock has a price-to-earnings ratio of 17.21.

As of 2025-12-14, Exelixis(EXEL) stock has fluctuated between $40.66 and $42.00. The current price stands at $40.88, placing the stock +0.5% above today's low and -2.7% off the high.

Exelixis(EXEL) shares are trading with a volume of 2.57M, against a daily average of 2.69M.

During the past year, Exelixis(EXEL) stock moved between $31.90 at its lowest and $49.62 at its peak.

During the past year, Exelixis(EXEL) stock moved between $31.90 at its lowest and $49.62 at its peak.

EXEL News

Simply Wall St 6d
Exelixis Valuation Check After Strong Multi‑Year Share Price Gains

Exelixis (EXEL) has quietly rewarded patient shareholders, with the stock up around 31% year to date and roughly 24% over the past year, outpacing many mid cap...

Exelixis Valuation Check After Strong Multi‑Year Share Price Gains
TipRanks 6d
Exelixis’s Oncology Potential: A Buy Rating Amid Evolving mCRC Treatment Landscape and Unmet Needs

Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis on December 5 and set a price target of $45.00. TipRanks Cyber Monday Sale Claim 60% off...

Analyst ratings

50%

of 22 ratings
Buy
50%
Hold
50%
Sell
0%

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.